CURRENT CHALLENGES & NEW THERAPEUTIC PROSPECTS TO FIGHT ALZHEIMER'S DISEASE

Thursday, September 29th (12h00-13h30)
Room C


Sponsored by:


A discussion panel with experts of the academia and industry

  1. Lessons learned from past Clinical Trials and what we need in the future tu cast better trials.
  2. How to navigate towards the Biomarker's Land, the Ithaca for the Neurodegenerative field.
  3. A brief review of the current therapeutic approaches. Have the mAb anti-abeta reached their momentum? Antagonists of the 5HT6 Receptor: incremental relief or game changers in alleviating symptoms?
  4. New targets and new approaches from Epigenetics to Gene-Therapy.
  5. Public-Academy Industry Collaborations: a success model?

Moderator:

Tamara Maes: Vice President & Chief Scientific Officer, ORYZON GENOMICS (Spain)

Speakers:

  • Harald J. Hampel: Professor, SORBONNE UNIVERSITIES (France)
  • Howard Fillit:  Founding Executive Director & CSO, ADDF-Alzheimer's Drug Discovery Foundation (USA)
  • Gurutz Linazasoro: CEO, VIVEbioTECH SL (Spain)